Pulmonary Drugs Market to Deliver Prominent Growth & Striking Opportunities From 2017 to 2025 Say SMI | Major Players Sanofi SA, Meda Pharmaceuticals, AstraZeneca Plc., GlaxoSmithKline Plc., Circassia Pharmaceuticals Plc., Alexia SAS

The Pulmonary Drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

The global pulmonary drug market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 – 2025).

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report @ https://www.stratagemmarketinsights.com/sample/12866

Market Dynamics:

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period.

For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

The major players operating the global pulmonary drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alexia SAS, and Merck Sharp & Dohme Limited.

Key features of the study:

1. This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

2. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

3. This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

4. It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans

5. Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

6. The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

7. Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Market synopsis:

Regional outlook:

- The report partitions the geographical landscape of the Pulmonary drugs market into Americas, APAC, Europe, Middle East & Africa.
- Evaluation of the economic indicators of the major economies and their influence on the overall industry growth is highlighted in the report.
- Consumption growth rate along with the projected market share of each region is given as well.

Product terrain outline:

- Market share based on consumption for each product type is listed.
- Records of the sales pricing and revenue accrued by each product category are tabulated.

Applications scope overview:

- Forecasts for the consumption value and share of each application segment over the analysis period are provided.
- Market share captured by each application type is included.

Quick Buy – Pulmonary Drugs Market Research Report: https://www.stratagemmarketinsights.com/cart/12866

Table of Contents

1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations

2. Market Purview
o Report Description
• Market Definition and Scope
o Executive Summary
• Market Snippet, By Drug Class
• Market Snippet, By Application
• Market Snippet, By Distribution Channel
• Market Snippet, By Region
o Stratagem Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Market Trends
o Regulatory Scenario
o Pipeline Analysis
o Promotional Activities and Campaigns
o Supply Chain Analysis
o PEST Analysis
o Epidemiology

4. Global Pulmonary Drugs Market, By Drug Class, 2017 – 2025, (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2025 (%)
• Y-o-Y Growth Analysis, 2017 – 2025
• Segment Trends
o Inhaled Corticosteroids
o Long-Acting Beta-2 Agonists
o Antihistamines
o Vasodilators
o Short-Acting Beta-2 Agonists
o Others

5. Global Pulmonary Drugs Market, By Application, 2017 – 2025, (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2025 (%)
• Y-o-Y Growth Analysis, 2017 – 2025
• Segment Trends
o Asthma & COPD
o Allergic Rhinitis
o Pulmonary Arterial Hypertension
o Cystic Fibrosis
o Others

6. Global Pulmonary Drugs Market, By Distribution Channel, 2017 – 2025, (US$ Million)
o Introduction
• Market Share Analysis, 2016 and 2025 (%)
• Y-o-Y Growth Analysis, 2017 – 2025
• Segment Trends
o Hospital Pharmacies
o Retail Pharmacies
o E-Commerce

7. Global Pulmonary Drugs Market, By Region, 2017 – 2025, (US$ Million)
o Introduction
• Market Share Analysis, By Region, 2016 and 2025 (%)
• Y-o-Y Growth Analysis, For Regions, 2017 – 2025
o North America
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• U.S.
• Canada
o Latin America
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• Brazil
• Mexico
• Rest of Latin America
o Europe
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
o Asia Pacific
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of APAC
o Middle East
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• GCC
• Israel
• Rest of Middle East
o Africa
• Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
• Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
• South Africa
• Central Africa
• North Africa

8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3×3 Matrix)
o Company Profiles
o Analyst Views

9. Section
o References
o Research Methodology
o About us and Sales Contact

For Any Enquiries/Customization Related Report click Here: https://www.stratagemmarketinsights.com/quiry/12866

Contact Us:

Mr. Shah
Stratagem Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737
Email: sales@stratagemmarketinsights.com
SJ

About Us:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our team includes analysts that leverage their years of experience and expertise to create accurate and error-free reports.

This release was published on openPR.